<n-docbody><doc bill="Y"><content.metadata.block><cmd.identifiers><cmd.cites><cmd.second.line.cite><bop/><bos/>Multidistrict Lit Man § 5:45<eos/><eop/></cmd.second.line.cite></cmd.cites></cmd.identifiers></content.metadata.block><prop.block><prop.head toc-guid=""><bop/><bos/><headtext>Multidistrict Litigation Manual</headtext><eos/><eop/></prop.head><content.metadata.block><cmd.dates><cmd.currency.default iso.d="20190501"><bop/><bos/>May 2019 Update<eos/><eop/></cmd.currency.default></cmd.dates></content.metadata.block><author.line><bop/><bos/><author>David F. Herr[<footnote.reference refid="If49376816b3e11e99b03e53d6dd36aa2">a0</footnote.reference>]</author><eos/><eop/></author.line><prop.head toc-guid="I97b7f560933b11da99e2b07024dacc26"><bop/><bos/><label.name>Part</label.name><label.designator>I.</label.designator><headtext>Handling Cases Before the Judicial Panel on Multidistrict Litigation</headtext><eos/><eop/></prop.head><prop.head toc-guid="Id8e3eb20933b11da99e2b07024dacc26"><bop/><bos/><label.name>Chapter</label.name><label.designator>5.</label.designator><headtext>Factors in Deciding Whether Transfer Is Appropriate</headtext><eos/><eop/></prop.head></prop.block><message.block><include.copyright n-include_collection="w_wlnv_msg" n-include_guid="I1DA35ED81DD211B281BAD200220BDFCA">Copyright (c) 2017 Thomson/RIA All rights reserved.</include.copyright></message.block><section><section.front><doc.title toc-guid="I94f30036e1e311da9c26e67ca3b71335"><head parent="doc.title"><bop/><bos/><label.name>§ </label.name><label.designator>5:45.</label.designator><headtext>Arguments rejected by the Panel—Differences in types of actions</headtext><eos/><eop/></head></doc.title></section.front><section.body><para><bop/><bos/><paratext>The Panel has rejected differences in the actions proposed to be transferred as a barrier to transfer for coordinated or consolidated pretrial proceedings. <eos/><bos/>The Panel will consider differences in the actions as a factor in determining whether the transfer would promote the just and efficient conduct of the litigation, but will not rule out transfer of different types of cases for this reason. <eos/><bos/>In one case the Panel ordered transfer of a group of actions involving claims by franchisees of a fast-food franchisor for coordinated or consolidated pretrial proceedings with a group of actions against the same franchisor despite the fact that those claims related to a different fast-food chain.[<eos/><bos/><footnote.reference refid="If4939d906b3e11e99b03e53d6dd36aa2">1</footnote.reference>] The Panel has ordered antitrust MDL proceedings and patent MDL proceedings transferred together.[<eos/><bos/><footnote.reference refid="If4939d916b3e11e99b03e53d6dd36aa2">2</footnote.reference>] In one decision, the Panel discusses the efficiencies than can be gained in transferring shareholder and derivative actions together.[<eos/><bos/><footnote.reference refid="If4939d926b3e11e99b03e53d6dd36aa2">3</footnote.reference>] The Panel has ordered transfer of additional product liability actions as tag-along actions despite the fact the claims involve different products than the pending actions.[<eos/><bos/><footnote.reference refid="If4939d936b3e11e99b03e53d6dd36aa2">4</footnote.reference>] Similarly, it has centralized in the first instance product liability claims involving different products.[<eos/><bos/><footnote.reference refid="If4939d946b3e11e99b03e53d6dd36aa2">5</footnote.reference>] It has declined to separate consumer claims and antitrust law claims, and ordered both types of actions together.[<eos/><bos/><footnote.reference refid="If4939d956b3e11e99b03e53d6dd36aa2">6</footnote.reference>] The argument that the actions are “different” just won&apos;t carry the day if, in fact, there are numerous fact similarities.[<eos/><bos/><footnote.reference refid="If493c4a06b3e11e99b03e53d6dd36aa2">7</footnote.reference>] The Panel regularly transfers securities and related ERISA actions for centralized proceedings,[<footnote.reference refid="If493c4a16b3e11e99b03e53d6dd36aa2">8</footnote.reference>] and has joined different actions asserting securities claims, derivative claims, and claims under ERISA in a single transfer order.[<eos/><bos/><footnote.reference refid="If494fd206b3e11e99b03e53d6dd36aa2">9</footnote.reference>] Similarly, citizen claims can be ordered to join municipal claims.[<eos/><bos/><footnote.reference refid="If49524306b3e11e99b03e53d6dd36aa2">10</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The key thing to remember is that the Panel is looking for similarity in the factual issues that will be the subject of pretrial discovery. <eos/><bos/>Similar cases involving different parties—where only a legal theory of recovery joins the actions—will not be viewed as benefitting from transfer.[<eos/><bos/><footnote.reference refid="If49524316b3e11e99b03e53d6dd36aa2">11</footnote.reference>] Cases arising from different courses of conduct may well not be transferred.[<eos/><bos/><footnote.reference refid="If49524326b3e11e99b03e53d6dd36aa2">12</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>One method used by the Panel to deal with claims that cases are dissimilar is to note that the transferee judge can manage the cases separately, ordering only, such common discovery and hearings as necessary.[<eos/><bos/><footnote.reference refid="If49524336b3e11e99b03e53d6dd36aa2">13</footnote.reference>] The Panel has also recognized that, if the claim of fundamental difference in the litigation is valid, the transferee judge can recommend early remand of the actions.[<eos/><bos/><footnote.reference refid="If49524346b3e11e99b03e53d6dd36aa2">14</footnote.reference>]</paratext><eos/><eop/></para><para><bop/><bos/><paratext>The Panel has also transferred cases involving claims relating to different security issues from a single issuer to a single judge for coordinated or consolidated pretrial proceedings.[<eos/><bos/><footnote.reference refid="If4954b426b3e11e99b03e53d6dd36aa2">15</footnote.reference>] The Panel rejected the arguments of a party contending that transfer should be denied because the transferee court would have to apply the substantive law of more than one state.[<eos/><bos/><footnote.reference refid="If49572506b3e11e99b03e53d6dd36aa2">16</footnote.reference>]</paratext><eos/><eop/></para></section.body></section><author.footnotes><footnote ID="If49376816b3e11e99b03e53d6dd36aa2"><label.designator>a0</label.designator><footnote.body><para><bop/><bos/><paratext>Maslon Edelman Borman &amp; Brand, LLP, Minneapolis, Minnesota.<eos/></paratext><eop/></para></footnote.body></footnote></author.footnotes><footnote.block><footnote ID="If4939d906b3e11e99b03e53d6dd36aa2"><label.designator>1</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="1972105315" w-seq-number="00001" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="950" ID="I825629a16b3e11e99f73e2698c313519">In re International House of Pancakes Franchise Litigation, 343 F. Supp. 948, 950 (J.P.M.L. 1972)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4939d916b3e11e99b03e53d6dd36aa2"><label.designator>2</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914047" w-serial-number="2001989477" w-seq-number="00002" w-ref-type="RP" w-pub-number="0004637" ID="I825677c16b3e11e99f73e2698c313519">In re Buspirone Patent Litigation, 176 F. Supp. 2d 1374 (J.P.M.L. 2001)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4939d926b3e11e99b03e53d6dd36aa2"><label.designator>3</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="2003470576" w-seq-number="00003" w-ref-type="RP" w-pub-number="0004637" ID="I825762216b3e11e99f73e2698c313519">In re Fleming Companies Inc. Securities and Derivative Litigation, 269 F. Supp. 2d 1374 (J.P.M.L. 2003)</cite.query>; <ital>see also</ital> <cite.query w-src-number="0304914047" w-serial-number="2002796688" w-seq-number="00004" w-ref-type="RP" w-pub-number="0004637" ID="I825762236b3e11e99f73e2698c313519">In re AOL Time Warner, Inc., 235 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query> (explaining why securities, derivative, and ERISA claims can be resolved together).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4939d936b3e11e99b03e53d6dd36aa2"><label.designator>4</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914047" w-serial-number="2001554355" w-seq-number="00005" w-ref-type="RP" w-pub-number="0004637" ID="I82584c816b3e11e99f73e2698c313519">In re Bridgestone/Firestone, Inc., Tires Products Liability Litigation, 151 F. Supp. 2d 1381 (J.P.M.L. 2001)</cite.query>. <eos/><bos/><ital>See also</ital> <cite.query w-src-number="0304914047" w-serial-number="2025869229" w-seq-number="00006" w-ref-type="RP" w-pub-number="0004637" ID="I82584c836b3e11e99f73e2698c313519">In re Zimmer Nexgen Knee Implant Products Liability Litigation, 802 F. Supp. 2d 1374 (J.P.M.L. 2011)</cite.query> (rejecting as barrier to transfer manufacturer&apos;s argument that cases involved eight different products, six design teams, and eight different FDA approvals); <cite.query w-src-number="0304914047" w-serial-number="2007685144" w-seq-number="00007" w-ref-type="RP" w-pub-number="0004637" ID="I82584c856b3e11e99f73e2698c313519">In re Guidant Corp. Implantable Defibrillators Products Liability Litigation, 398 F. Supp. 2d 1371 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2007906257" w-seq-number="00008" w-ref-type="RP" w-pub-number="0004637" ID="I82584c876b3e11e99f73e2698c313519">In re Medtronic, Inc., Implantable Defibrillators Products Liability Litigation, 408 F. Supp. 2d 1351 (J.P.M.L. 2005)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4939d946b3e11e99b03e53d6dd36aa2"><label.designator>5</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914047" w-serial-number="2007286472" w-seq-number="00009" w-ref-type="RP" w-pub-number="0004637" ID="I8258e8c16b3e11e99f73e2698c313519">In re Bextra and Celebrex Marketing, Sales Practices and Products Liability Litigation, 391 F. Supp. 2d 1377 (J.P.M.L. 2005)</cite.query>. <eos/><bos/><ital>But see</ital> <cite.query w-src-number="0304914047" w-serial-number="2006243939" w-seq-number="00010" w-ref-type="RP" w-pub-number="0004637" ID="I8258e8c36b3e11e99f73e2698c313519"><ital>In re Vioxx Products Liability Litigation</ital>, 360 F. Supp. 2d 1352 (J.P.M.L. 2005)</cite.query> (all actions <case.history>transferred</case.history> except for single action involving a different drug).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4939d956b3e11e99b03e53d6dd36aa2"><label.designator>6</label.designator><footnote.body><para><bop/><bos/><paratext><cite.query w-src-number="0304914047" w-serial-number="2001556902" w-seq-number="00011" w-ref-type="RP" w-pub-number="0004637" ID="I82595df16b3e11e99f73e2698c313519">In re StarLink Corn Products Liability Litigation, 152 F. Supp. 2d 1378 (J.P.M.L. 2001)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If493c4a06b3e11e99b03e53d6dd36aa2"><label.designator>7</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="2034645472" w-seq-number="00012" w-ref-type="RP" w-pub-number="0007903" ID="I825a48516b3e11e99f73e2698c313519">In re: Cook Medical, Inc., IVC Filters Marketing, Sales Practices and Products Liability Litigation, 53 F. Supp. 3d 1379 (U.S.J.P.M.L. 2014)</cite.query> (centralization ordered despite different products involved); <cite.query w-src-number="0304914047" w-serial-number="2034645489" w-seq-number="00013" w-ref-type="RP" w-pub-number="0007903" ID="I825a48536b3e11e99f73e2698c313519">In re: Impulse Monitoring, Inc., Aetna Intraoperative Monitoring Services Claims and Employee Retirement Income Sec. Act (ERISA) Litigation, 53 F. Supp. 3d 1376 (U.S.J.P.M.L. 2014)</cite.query> (different patients and insurance plans, but centralization ordered); <cite.query w-src-number="0304914047" w-serial-number="2002286701" w-seq-number="00014" w-ref-type="RP" w-pub-number="0004637" ID="I825a48556b3e11e99f73e2698c313519">In re Immunex Corp. Average Wholesale Price Litigation, 201 F. Supp. 2d 1378 (J.P.M.L. 2002)</cite.query> (request to transfer actions in different groups <case.history>denied</case.history>; single transfer ordered).<eos/><bos/> <ital>But see</ital> <cite.query w-src-number="0304914047" w-serial-number="2034977728" w-seq-number="00015" w-ref-type="RP" w-pub-number="0007903" ID="I825a48576b3e11e99f73e2698c313519">In re: OxyElite Pro and Jack3d Products Liability Litigation (No. II), 65 F. Supp. 3d 1412 (U.S.J.P.M.L. 2014)</cite.query> (<case.history>transfer denied</case.history> where products have different formulas, different alleged health risks, and distinct regulatory responses to issues).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If493c4a16b3e11e99b03e53d6dd36aa2"><label.designator>8</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914047" w-serial-number="2017563802" w-seq-number="00016" w-ref-type="RP" w-pub-number="0004637" ID="I825d07716b3e11e99f73e2698c313519">In re National City Corp. Securities, Derivative and Employee Retirement Income Sec. Act (ERISA) Litigation, 588 F. Supp. 2d 1362 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2016825463" w-seq-number="00017" w-ref-type="RP" w-pub-number="0004637" ID="I825d07736b3e11e99f73e2698c313519">In re Bear Stearns Companies Inc. Securities, Derivative and Employee Retirement Income Security Act (ERISA) Litigation, 572 F. Supp. 2d 1377 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2015730643" w-seq-number="00018" w-ref-type="RP" w-pub-number="0004637" ID="I825d07756b3e11e99f73e2698c313519">In re Merrill Lynch &amp; Co., Inc., Securities, Derivative &amp; ERISA Litigation, 542 F. Supp. 2d 1374 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2015333561" w-seq-number="00019" w-ref-type="RP" w-pub-number="0004637" ID="I825d07776b3e11e99f73e2698c313519">In re Washington Mut., Inc., Securities, Derivative &amp; ERISA Litigation, 536 F. Supp. 2d 1377 (J.P.M.L. 2008)</cite.query>; In re <cite.query w-src-number="0304914047" w-serial-number="2006842217" w-seq-number="00020" w-ref-type="RP" w-pub-number="0004637" ID="I825d07796b3e11e99f73e2698c313519">Pfizer Ins. Securities, Derivative &amp; ERISA Litigation, 374 F. Supp. 2d 1348 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2006671811" w-seq-number="00021" w-ref-type="RP" w-pub-number="0004637" ID="I825d077b6b3e11e99f73e2698c313519">In re Federal Nat. Mortg. Ass&apos;n Securities Derivative &amp; “ERISA” Litigation, 370 F. Supp. 2d 1359 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2006294264" w-seq-number="00022" w-ref-type="RP" w-pub-number="0004637" ID="I825d077d6b3e11e99f73e2698c313519">In re Merck &amp; Co., Inc., Securities, Derivative &amp; ERisa Litigation, 360 F. Supp. 2d 1375 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2003469302" w-seq-number="00023" w-ref-type="RP" w-pub-number="0004637" ID="I825d077f6b3e11e99f73e2698c313519">In re Royal Ahold N.V. Securities, “ERISA” Litigation, 269 F. Supp. 2d 1362 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2003212316" w-seq-number="00024" w-ref-type="RP" w-pub-number="0004637" ID="I825d07816b3e11e99f73e2698c313519">In re Electronic Data Systems Corp. Securities &amp; “ERISA” Litigation, 254 F. Supp. 2d 1375 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2003212315" w-seq-number="00025" w-ref-type="RP" w-pub-number="0004637" ID="I825d07836b3e11e99f73e2698c313519">In re Xcel Energy, Inc., 254 F. Supp. 2d 1368 (J.P.M.L. 2003)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002796688" w-seq-number="00026" w-ref-type="RP" w-pub-number="0004637" ID="I825d07856b3e11e99f73e2698c313519">In re AOL Time Warner, Inc., 235 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002666767" w-seq-number="00027" w-ref-type="RP" w-pub-number="0004637" ID="I825d07876b3e11e99f73e2698c313519">In re Enron Corp. Securities, Derivative &amp; “ERISA” Litigation, 227 F. Supp. 2d 1389 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002579289" w-seq-number="00028" w-ref-type="RP" w-pub-number="0004637" ID="I825d07896b3e11e99f73e2698c313519">In re Global Crossing Ltd. Securities &amp; “ERISA” Litigation, 223 F. Supp. 2d 1384 (J.P.M.L. 2002)</cite.query>; <ital>accord</ital> <cite.query w-src-number="0304914047" w-serial-number="2003462010" w-seq-number="00029" w-ref-type="RP" w-pub-number="0004637" ID="I825d078b6b3e11e99f73e2698c313519">In re Nortel Networks Corp. Securities &amp; “ERISA” Litigation, 269 F. Supp. 2d 1367 (J.P.M.L. 2003)</cite.query> (Panel transfers ERISA cases only, but reason is that securities cases have been pending and would not benefit from centralization).<eos/><bos/> Arguing against the centralization of ERISA and securities claims is not likely to be successful. <eos/><bos/><ital>See, e.g.,</ital> <cite.query w-src-number="0304914047" w-serial-number="2007915636" w-seq-number="00030" w-ref-type="RP" w-pub-number="0004637" ID="I825d078d6b3e11e99f73e2698c313519">In re Delphi Corp. Securities, Derivative and “ERISA” Litigation, 403 F. Supp. 2d 1358 (J.P.M.L. 2005)</cite.query>. <eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If494fd206b3e11e99b03e53d6dd36aa2"><label.designator>9</label.designator><footnote.body><para><bop/><bos/><paratext> <cite.query w-src-number="0304914047" w-serial-number="2003613128" w-seq-number="00031" w-ref-type="RP" w-pub-number="0004637" ID="I825f03416b3e11e99f73e2698c313519">In re Unumprovident Corp. Securities, Derivative &amp; “ERISA” Litigation, 280 F. Supp. 2d 1377 (J.P.M.L. 2003)</cite.query>. <eos/><bos/><ital>See also </ital> <cite.query w-src-number="0304914047" w-serial-number="2019111512" w-seq-number="00032" w-ref-type="RP" w-pub-number="0004637" ID="I825f03436b3e11e99f73e2698c313519">In re Zimmer Holdings, Inc., Securities, Derivative and Employee Retirement Income Sec. Act (ERISA) Litigation, 626 F. Supp. 2d 1319 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2019111918" w-seq-number="00033" w-ref-type="RP" w-pub-number="0004637" ID="I825f03456b3e11e99f73e2698c313519">In re Bank of America Corp. Securities, Derivative and Employee Retirement Income Sec. Act (ERISA) Litigation, 626 F. Supp. 2d 1327 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2018178665" w-seq-number="00034" w-ref-type="RP" w-pub-number="0004637" ID="I825f03476b3e11e99f73e2698c313519">In re Regions Morgan Keegan Securities, Derivative and Employee Retirement Income Security Act (ERISA) Litigation, 598 F. Supp. 2d 1379 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2016330752" w-seq-number="00035" w-ref-type="RP" w-pub-number="0004637" ID="I825f03496b3e11e99f73e2698c313519">In re State Street Bank and Trust Co. Fixed Income Funds Inv. Litigation, 560 F. Supp. 2d 1388 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2006294264" w-seq-number="00036" w-ref-type="RP" w-pub-number="0004637" ID="I825f034b6b3e11e99f73e2698c313519">In re Merck &amp; Co., Inc., Securities, Derivative &amp; ERISA Litigation, 360 F. Supp. 2d 1375 (J.P.M.L. 2005)</cite.query> (Panel notes that actions by securities holders, derivative claims, or participants in retirement savings plans all expected to focus on common events, documents, witnesses); In re <cite.query w-src-number="0304914047" w-serial-number="2006842217" w-seq-number="00037" w-ref-type="RP" w-pub-number="0004637" ID="I825f034d6b3e11e99f73e2698c313519">Pfizer Ins. Securities, Derivative &amp; ERISA Litigation, 374 F. Supp. 2d 1348 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002796688" w-seq-number="00038" w-ref-type="RP" w-pub-number="0004637" ID="I825f034f6b3e11e99f73e2698c313519">In re AOL Time Warner, Inc., 235 F. Supp. 2d 1380 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002666767" w-seq-number="00039" w-ref-type="RP" w-pub-number="0004637" ID="I825f03516b3e11e99f73e2698c313519">In re Enron Corp. Securities, Derivative &amp; “ERISA” Litigation, 227 F. Supp. 2d 1389 (J.P.M.L. 2002)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49524306b3e11e99b03e53d6dd36aa2"><label.designator>10</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="2003300480" w-seq-number="00040" w-ref-type="RP" w-pub-number="0004637" ID="I825fc6916b3e11e99f73e2698c313519">In re Ford Motor Co. Crown Victoria Police Interceptor Products Liability Litigation, 259 F. Supp. 2d 1366 (J.P.M.L. 2003)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49524316b3e11e99b03e53d6dd36aa2"><label.designator>11</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="2005443071" w-seq-number="00041" w-ref-type="RP" w-pub-number="0004637" ID="I826089e16b3e11e99f73e2698c313519">In re American Airlines, Inc., Privacy Litigation, 342 F. Supp. 2d 1355 (J.P.M.L. 2004)</cite.query> (Panel declines to transfer to permit coordination with similar cases against wholly unrelated party); <cite.query w-src-number="0304914047" w-serial-number="2005396813" w-seq-number="00042" w-ref-type="RP" w-pub-number="0004637" ID="I826089e36b3e11e99f73e2698c313519">In re Not-For-Profit Hospitals/Uninsured Patients Litigation, 341 F. Supp. 2d 1354 (J.P.M.L. 2004)</cite.query> (transfer declined in multiple claims against unrelated hospital relating to different pricing practices).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49524326b3e11e99b03e53d6dd36aa2"><label.designator>12</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914047" w-serial-number="2002666767" w-seq-number="00043" w-ref-type="RP" w-pub-number="0004637" ID="I8260ff116b3e11e99f73e2698c313519">In re Enron Corp. Securities, Derivative &amp; “ERISA” Litigation, 227 F. Supp. 2d 1389 (J.P.M.L. 2002)</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49524336b3e11e99b03e53d6dd36aa2"><label.designator>13</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.</ital>, <cite.query w-src-number="0304914047" w-serial-number="2009728551" w-seq-number="00044" w-ref-type="RP" w-pub-number="0004637" ID="I8261e9716b3e11e99f73e2698c313519">In re National Sec. Agency Telecommunications Records Litigation, 444 F. Supp. 2d 1332 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002579289" w-seq-number="00045" w-ref-type="RP" w-pub-number="0004637" ID="I8261e9736b3e11e99f73e2698c313519">In re Global Crossing Ltd. Securities &amp; “ERISA” Litigation, 223 F. Supp. 2d 1384 (J.P.M.L. 2002)</cite.query> (Panel orders both ERISA and securities <case.history>cases transferred</case.history>, noting that transferee court can determine extent of coordination).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49524346b3e11e99b03e53d6dd36aa2"><label.designator>14</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914047" w-serial-number="2019111284" w-seq-number="00046" w-ref-type="RP" w-pub-number="0004637" ID="I826349016b3e11e99f73e2698c313519">In re Kaplan Higher Educ. Corp. Qui Tam Litigation, 626 F. Supp. 2d 1323 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2019111935" w-seq-number="00047" w-ref-type="RP" w-pub-number="0004637" ID="I826349036b3e11e99f73e2698c313519">In re Citigroup, Inc., Auction Rate Securities (ARS) Marketing Litigation (No. II), 626 F. Supp. 2d 1329 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2018194272" w-seq-number="00048" w-ref-type="RP" w-pub-number="0004637" ID="I826349056b3e11e99f73e2698c313519">In re Chrysler LLC 2.7 Liter V-6 Engine Oil Sludge Products Liability Litigation, 598 F. Supp. 2d 1372 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2018178447" w-seq-number="00049" w-ref-type="RP" w-pub-number="0004637" ID="I826349086b3e11e99f73e2698c313519">In re Bank of America Corp. Auction Rate Securities (ARS) Marketing Litigation, 598 F. Supp. 2d 1377 (J.P.M.L. 2009)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2017563802" w-seq-number="00050" w-ref-type="RP" w-pub-number="0004637" ID="I8263490a6b3e11e99f73e2698c313519">In re National City Corp. Securities, Derivative and Employee Retirement Income Sec. Act (ERISA) Litigation, 588 F. Supp. 2d 1362 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2015776116" w-seq-number="00051" w-ref-type="RP" w-pub-number="0004637" ID="I8263490c6b3e11e99f73e2698c313519">In re Pet Food Products Liability Litigation, 544 F. Supp. 2d 1378 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2015774352" w-seq-number="00052" w-ref-type="RP" w-pub-number="0004637" ID="I8263490e6b3e11e99f73e2698c313519">In re Medtronic, Inc., Implantable Defibrillators Products Liability Litigation, 543 F. Supp. 2d 1371 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2015776111" w-seq-number="00053" w-ref-type="RP" w-pub-number="0004637" ID="I826349106b3e11e99f73e2698c313519">In re Ford Motor Co. Speed Control Deactivation Switch Products Liability Litigation, 543 F. Supp. 2d 1373 (J.P.M.L. 2008)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2006265212" w-seq-number="00054" w-ref-type="RP" w-pub-number="0004637" ID="I826349126b3e11e99f73e2698c313519">In re Insurance Brokerage Antitrust Litigation, 360 F. Supp. 2d 1371 (J.P.M.L. 2005)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2002656612" w-seq-number="00055" w-ref-type="RP" w-pub-number="0004637" ID="I826349146b3e11e99f73e2698c313519">In re Merrill Lynch &amp; Co., Inc., Research Reports Securities Litigation, 223 F. Supp. 2d 1388 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2009773308" w-seq-number="00056" w-ref-type="RP" w-pub-number="0004637" ID="I826349166b3e11e99f73e2698c313519">In re Qwest Communications Intern., Inc., Securities &amp; “ERISA” Litigation (No. II), 444 F. Supp. 2d 1343 (J.P.M.L. 2006)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="2009728551" w-seq-number="00057" w-ref-type="RP" w-pub-number="0004637" ID="I826349186b3e11e99f73e2698c313519">In re National Sec. Agency Telecommunications Records Litigation, 444 F. Supp. 2d 1332 (J.P.M.L. 2006)</cite.query>. <eos/><bos/><cite.query w-src-number="0304914047" w-serial-number="1971106508" w-seq-number="00058" w-ref-type="RP" w-pub-number="0000345" ID="I8263491a6b3e11e99f73e2698c313519">In re Seeburg-Commonwealth United Merger, 331 F. Supp. 552 (J.P.M.L. 1971)</cite.query>. <eos/><bos/>The Panel&apos;s views favoring wide latitude to the transferee court are discussed in greater detail in Chapter 9. The possibility of separate and early remand are discussed in §§ <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs5:56" w-pub-number="185218" ID="If4954b406b3e11e99b03e53d6dd36aa2">5:56</cite.query> to  <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs5:59" w-pub-number="185218" ID="If4954b416b3e11e99b03e53d6dd36aa2">5:59</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If4954b426b3e11e99b03e53d6dd36aa2"><label.designator>15</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See, e.g.,</ital> <cite.query w-src-number="0304914047" w-serial-number="2002789218" w-seq-number="00059" w-ref-type="RP" w-pub-number="0004637" ID="I826481816b3e11e99f73e2698c313519">In re Pharmaceutical Industry Average Wholesale Price Litigation, 237 F. Supp. 2d 1377 (J.P.M.L. 2002)</cite.query>; <cite.query w-src-number="0304914047" w-serial-number="1971104462" w-seq-number="00060" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="1022" ID="I826481836b3e11e99f73e2698c313519">In re Penn Cent. Securities Litigation, 322 F. Supp. 1021, 1022–23 (J.P.M.L. 1971)</cite.query> (stock cases and bond <case.history>cases transferred</case.history>).<eos/><bos/> <ital>But see</ital> <cite.query w-src-number="0304914047" w-serial-number="1971104969" w-seq-number="00061" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="311" ID="I826481856b3e11e99f73e2698c313519">In re Penn Cent. Securities Litigation, 325 F. Supp. 309, 311 (J.P.M.L. 1971)</cite.query> (cases involving commercial paper <case.history>transferred</case.history> to different district from previously transferred stock and bond cases).<eos/></paratext><eop/></para></footnote.body></footnote><footnote ID="If49572506b3e11e99b03e53d6dd36aa2"><label.designator>16</label.designator><footnote.body><para><bop/><bos/><paratext><ital>See</ital> <cite.query w-src-number="0304914047" w-serial-number="1978103749" w-seq-number="00062" w-ref-type="RP" w-pub-number="0000345" w-pinpoint-page="449" ID="I82651dc16b3e11e99f73e2698c313519">In re Helicopter Crash in Germany on September 26, 1975, 443 F. Supp. 447, 449 (J.P.M.L. 1978)</cite.query>. <eos/><bos/>Questions concerning choice of law in the transferred actions is discussed in <cite.query w-ref-type="NA" w-normalized-cite="MDLITMANs9:8" w-pub-number="185218" ID="If49572516b3e11e99b03e53d6dd36aa2">§ 9:8</cite.query>.<eos/></paratext><eop/></para></footnote.body></footnote></footnote.block><content.metadata.block><cmd.royalty><cmd.copyright><bop/><bos/>Westlaw. © 2019 Thomson Reuters.  <eos/><bos/>No Claim to Orig. U.S. Govt. <eos/><bos/>Works.<eos/><eop/></cmd.copyright></cmd.royalty><cmd.identifiers><cmd.cites><cmd.first.line.cite><bop/><bos/>MDLITMAN § 5:45<eos/><eop/></cmd.first.line.cite></cmd.cites></cmd.identifiers></content.metadata.block></doc></n-docbody>
